08:00 Mon 01 Apr 2019
Polarean Imaging PLC - Amphion Innovations - Pledge of Polarean shares
("Polarean" or the "Company")
Amphion Innovations plc - Pledge of Polarean shares
Amphion has transferred the legal title to, but retains the beneficial interest in, the pledged shares in Polarean. In addition, the Lender has agreed to adhere to the terms of an orderly market agreement for the next 12 months with regards to the 18,372,523 Polarean shares.
The full announcement from Amphion is available here
http://www.rns-pdf.londonstockexchange.com/rns/5605U_1-2019-3-29.pdf
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").
Enquiries:
|
|||
|
Via Walbrook PR |
||
|
|
||
|
|
||
|
Tel: +44 (0)20 3470 0470 |
||
|
|
||
|
|
||
|
|
||
MC Services (European IR) |
Tel: +49 (0)89 210 2280 |
||
|
|
||
|
|
||
Walbrook PR |
Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com |
||
|
Mob: +44 (0)7980 541 893 / +44 (0)7879 741 001 |
||
About Polarean (www.polarean.com)
The Company and its wholly owned subsidiary,
The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas (129Xe) as an imaging agent to visualise ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.
The Group operates in an area of significant unmet medical need and the Group's technology provides a novel diagnostic approach, offering a non-invasive and radiation-free functional imaging platform which is more accurate than current methods. The annual burden of pulmonary disease in the US is estimated to be over US
The Group is currently undertaking Phase III Non-Inferiority Clinical Trials for 129Xe at
This information is provided by RNS, the news service of the
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE